Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?

Yonsei Medical Journal

Volumn 49, Issue 4, 2008, Pages 545-552

  Rha, Dong Wook ^a   Yang, Eun Joo ^a   Chung, Ho Ik ^a   Kim, Hyoung Bin ^a   Park, Chang Il ^a   Park, Eun Sook ^a  

^a Yonsei University   (South Korea)

Author keywords

Botulinum toxin type A; Cerebral palsy; Electrical stimulation; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ACTION POTENTIAL; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION THERAPY; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; JOINT MOBILITY; KNEE FUNCTION; MALE; MEDICAL ASSESSMENT; MUSCLE DENERVATION; MUSCLE TONE; RATING SCALE; SPASTICITY; TIME; TREATMENT OUTCOME;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD, PRESCHOOL; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; PARALYSIS;

EID: 52949093122     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.4.545     Document Type: Article

References (31)

1. Mongan D, Dunne K, O'Nuallain S, Gaffney G. Prevalence of cerebral palsy in the West of Ireland 1990-1999. Dev Med Child Neurol 2006;48:892-5.
2. Platt MJ, Cans C, Johnson A, Surman G, Topp M, Torrioli MG, et al. Trends in cerebral palsy among infants of very low birthweight (< 1500g) or born prematurely (< 32 weeks) in 16 European centres: a database study. Lancet 2007;369:43-50.
3. Corry IS. Use of a motion analysis laboratory in assessing the effects of botulinum toxin in a cerebral palsy [dissertation]. Thesis for doctor of medicine in the faculty of medicine. Belfast (North Ireland): The Queens University; 1995.
4. Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994;36:379-85.
5. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5.
6. Lance JW. Pathophysiology of spasticity and clinical experience of baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p.185-203.
7. Ziv I, Blackburn N, Rang M, Koreska J. Muscle growth in normal and spastic mice. Dev Med Child Neurol 1984;26:94-9.
8. Mohamed KA, Moore AP, Rosenbloom L. Adverse events following repeated injections with botulinum toxin A in children with spasticity. Dev Med Child Neurol 2001;43:791.
9. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8 Suppl 5:21-9.
10. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997;12:89-94.
11. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40.
12. Hughes R, Whaler BC. Inffluence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by C1. botulinum type A toxin. J Physiol 1962;160:221-33.
13. Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, Suh YL, et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-6.
14. Frasson E, Priori A, Ruzzante B, Didone G, Bertolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord 2005;20:624-9.
15. Detrembleur C, Lejeune TM, Renders A, Van Den Bergh PY. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Mov Disord 2002;17:162-9.
16. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-8.
17. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-23.
18. Seo JH, Kim SS, Kim NK, Lee JH. Measuring compound muscle action potentials after botulinum toxin a injection for the quantification of effects. J Korean Acad Rehabil Med 1998;22:1225-31.
19. Yam WK, Leung MS. Interrater reliability of Modified Ashworth Scale and Modified Tardieu Scale in children with spastic cerebral palsy. J Child Neurol 2006;21: 1031-5.
20. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999;354:259-68.
21. Das Gupta BR, Sugiyama H. Role of a protease in natural activation of Clostridium botulinum neurotoxin. Infect Immun 1972;6:587-90.
22. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
23. Kesar T, Chou LW, Binder-Macleod SA. Effects of stimulation frequency versus pulse duration modulation on muscle fatigue. J Electromyogr Kinesiol 2007; 18:662-71.
24. Kesar T, Binder-Macleod S. Effect of frequency and pulse duration on human muscle fatigue during repetitive electrical stimulation. Exp Physiol 2006;91: 967-76.
25. Johnson C, Wood DE, Swain ID, Tromans AM, Strike P, Burridge JH. A pilot study to investigate the combined use of botulinum neurotoxin type a and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs 2002;26:263-6.
26. Carda S, Molteni F. Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study. Clin Rehabil 2005;19:621-6.
27. Rodriquez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44-7.
28. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999;13: 373-83.
29. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 2001;8 Suppl 5:50-8.
30. Mehrholz J, Wagner K, Meissner D, Grundmann K, Zange C, Koch R, et al. Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil 2005;19:751-9.
31. Sätilä H, Iisalo T, Pietikäinen T, Seppänen RL, Salo M, Koivikko M, et al. Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites. Am J Phys Med Rehabil 2005;84: 355-65; quiz 66-7, 392.